Credit Suisse’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $17.3M | Buy |
143,776
+10,285
| +8% | +$1.26M | 0.02% | 680 |
|
|
2023
Q4 | $16.4M | Sell |
133,491
-1,298
| -1% | -$162K | 0.02% | 720 |
|
|
2023
Q3 | $17.4M | Sell |
134,789
-3,122
| -2% | -$416K | 0.02% | 679 |
|
|
2023
Q2 | $17.1M | Sell |
137,911
-9,223
| -6% | -$1.24M | 0.02% | 724 |
|
|
2023
Q1 | $21.5M | Buy |
147,134
+29,500
| +25% | +$4.36M | 0.02% | 651 |
|
|
2022
Q4 | $18.7M | Buy |
117,634
+8,409
| +8% | +$1.23M | 0.02% | 694 |
|
|
2022
Q3 | $14.6M | Buy |
109,225
+15,673
| +17% | +$2.38M | 0.02% | 765 |
|
|
2022
Q2 | $14.6M | Sell |
93,552
-4,285
| -4% | -$660K | 0.02% | 789 |
|
|
2022
Q1 | $15.2M | Buy |
97,837
+681
| +0.7% | +$98.8K | 0.01% | 869 |
|
|
2021
Q4 | $12.4M | Sell |
97,156
-4,592
| -5% | -$603K | 0.01% | 1347 |
|
|
2021
Q3 | $13.2M | Sell |
101,748
-27,116
| -21% | -$4.1M | 0.01% | 1348 |
|
|
2021
Q2 | $22.9M | Sell |
128,864
-2,321
| -2% | -$402K | 0.01% | 1078 |
|
|
2021
Q1 | $21.6M | Buy |
131,185
+22,655
| +21% | +$3.73M | 0.01% | 1119 |
|
|
2020
Q4 | $17.9M | Sell |
108,530
-13,308
| -11% | -$1.98M | 0.01% | 1232 |
|
|
2020
Q3 | $17.4M | Sell |
121,838
-16,477
| -12% | -$2.04M | 0.01% | 1106 |
|
|
2020
Q2 | $15.3M | Sell |
138,315
-84,944
| -38% | -$9.39M | 0.01% | 1086 |
|
|
2020
Q1 | $22.3M | Buy |
223,259
+48,015
| +27% | +$6.21M | 0.02% | 788 |
|
|
2019
Q4 | $26.2M | Buy |
175,244
+91,606
| +110% | +$12.5M | 0.02% | 882 |
|
|
2019
Q3 | $10.7M | Sell |
83,638
-15,798
| -16% | -$2.12M | 0.01% | 1264 |
|
|
2019
Q2 | $14.2M | Sell |
99,436
-6,017
| -6% | -$809K | 0.01% | 1113 |
|
|
2019
Q1 | $15.1M | Buy |
105,453
+8,712
| +9% | +$1.14M | 0.01% | 1005 |
|
|
2018
Q4 | $12M | Buy |
96,741
+3,502
| +4% | +$520K | 0.01% | 1059 |
|
|
2018
Q3 | $15.7M | Buy |
93,239
+2,158
| +2% | +$371K | 0.01% | 999 |
|
|
2018
Q2 | $15.7M | Buy |
91,081
+223
| +0.2% | +$36.5K | 0.02% | 975 |
|
|
2018
Q1 | $13.7M | Sell |
90,858
-106
| -0.1% | -$15.5K | 0.01% | 1067 |
|
|
2017
Q4 | $12.2M | Buy |
90,964
+21,930
| +32% | +$3.04M | 0.01% | 1138 |
|
|
2017
Q3 | $10.1M | Sell |
69,034
-29,337
| -30% | -$4.44M | 0.01% | 1249 |
|
|
2017
Q2 | $15.3M | Buy |
98,371
+20,562
| +26% | +$3.14M | 0.01% | 947 |
|
|
2017
Q1 | $11.3M | Sell |
77,809
-32,645
| -30% | -$4.25M | 0.01% | 1145 |
|
|
2016
Q4 | $12M | Buy |
110,454
+5,469
| +5% | +$609K | 0.01% | 1089 |
|
|
2016
Q3 | $12.8M | Sell |
104,985
-120,330
| -53% | -$16.2M | 0.01% | 1048 |
|
|
2016
Q2 | $31.8M | Buy |
225,315
+98,322
| +77% | +$14.5M | 0.04% | 561 |
|
|
2016
Q1 | $16.6M | Sell |
126,993
-1,342
| -1% | -$167K | 0.02% | 814 |
|
|
2015
Q4 | $18M | Buy |
128,335
+5,484
| +4% | +$760K | 0.02% | 832 |
|
|
2015
Q3 | $16.3M | Sell |
122,851
-47,438
| -28% | -$8.17M | 0.02% | 858 |
|
|
2015
Q2 | $30M | Sell |
170,289
-25,692
| -13% | -$4.61M | 0.03% | 621 |
|
|
2015
Q1 | $33.9M | Buy |
195,981
+26,781
| +16% | +$4.6M | 0.03% | 571 |
|
|
2014
Q4 | $27.7M | Buy |
169,200
+53,401
| +46% | +$8.86M | 0.02% | 717 |
|
|
2014
Q3 | $18.6M | Buy |
115,799
+6,551
| +6% | +$1.01M | 0.02% | 956 |
|
|
2014
Q2 | $16.1M | Buy |
109,248
+172
| +0.2% | +$23.9K | 0.01% | 1075 |
|
|
2014
Q1 | $15.1M | Buy |
109,076
+32,963
| +43% | +$4.96M | 0.01% | 984 |
|
|
2013
Q4 | $9.63M | Buy |
76,113
+8,420
| +12% | +$871K | 0.01% | 1305 |
|
|
2013
Q3 | $6.22M | Sell |
67,693
-80,666
| -54% | -$6.51M | 0.01% | 1469 |
|
|
2013
Q2 | $10.2M | Buy |
+148,359
| New | +$9.07M | 0.01% | 1120 |
|
Other funds holding JAZZ
PCM
Credit Suisse's JAZZ Position: Q1 2024 in Review
Credit Suisse increased its Jazz Pharmaceuticals (JAZZ) stake by 7.7% in Q1 2024, buying an estimated $1.26M and bringing the position to 143,776 shares worth $17.3M. The position accounts for 0.02% of the portfolio, ranked #680.
Credit Suisse first reported a position in JAZZ in Q2 2013 and has held it in 44 quarters since. The position peaked at $33.9M in Q1 2015. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.
- Credit Suisse held 143,776 shares of Jazz Pharmaceuticals worth $17.3M as of Q1 2024.
- Credit Suisse bought 10,285 Jazz Pharmaceuticals shares in Q1 2024, an estimated $1.26M.
- Jazz Pharmaceuticals made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #680 holding.
- Credit Suisse first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Jazz Pharmaceuticals position peaked at $33.9M in Q1 2015.
- 480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.